Guidelines for the antidiabetic assay for bioactive substances in cell model

Abstract

Diabetes is a group of metabolic diseases characterized by hyperglycemia. Insulin resistance (IR) and insufficient insulin secretion are important pathophysiological basis and significant characteristics of diabetes. At present, animal is still the main model for investigation of Antidiabetic activity of bioactive substances, however, in vivo models always has the problems of long experimental cycle, complicated experiment, and high cost. Compared with the animal models, cell culture could avoid some impossible or difficult to eliminate under natural conditions, and observe the experimental results more simply, economically, quickly, and objectively. In this case, the establishment of in vitro diabetic cell model has gradually developed. Recently, cell models are more widely used in highthroughput screening, metabolism analysis, molecular pharmacology investigation, pharmacodynamics evaluation of natural product, cell function, interaction between receptors and cytokines, and so on. These guidelines will point out and discuss to help researchers to choose cell model that are truly reliable and can be successfully applied for their intended investigation of antidiabetic activity.

Potential hypoglycemic and hypolipidemic bioactive constituents in Cyclocarya paliurus leaves explored by affinity ultrafiltration with α‐glucosidase and pancreatic lipase

“…Diabetes mellitus (DM), mainly characterized by prolonged hyperglycemia, has long been a serious chronic metabolic disease that imposes severe healthcare burdens and affects life quality globally (Pirola et al, 2010; Tremblay & Hamet, 2019). The over‐secretion of insulin or disturbance of insulin action lead to dysfunction of blood glucose, causing multicomplications with high mortality and morbidity (Roham et al, 2022; Teng et al, 2022). The increasing prevalence of diabetes alarms a remaining large portion of patients with glycemic control deficiency (Wang et al, 2021).…”